Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Atezolizumab in Combination With Bevacizumab and Chemotherapy Versus Bevacizumab and Chemotherapy in Recurrent Ovarian Cancer - a Randomized Phase III Trial

NCT03353831 is registered in ClinicalTrials.gov with AGO Research GmbH as lead sponsor.

NCT NCT03353831
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03353831 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Atezolizumab in Combination With Bevacizumab and Chemotherapy Versus Bevacizumab and Chemotherapy in Recurrent Ovarian Cancer - a Randomized Phase III Trial
Lead sponsor
AGO Research GmbH
Phase
Phase 3
Overall status
Completed
Start date
September 11, 2018
Completion date
March 11, 2025
Enrollment
574 (actual)
Sites
111

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent ovarian carcinoma